Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants
暂无分享,去创建一个
Hengli Zhao | Qing Wen | Shaorong Li | Xiaoran Zhang | Gexin Shi | Jing Rao
[1] Xiaoping Cai,et al. Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis , 2022, Pharmacology.
[2] Ping Shi,et al. The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects , 2022, Cancer Chemotherapy and Pharmacology.
[3] Ting Dou,et al. Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects , 2022, Investigational New Drugs.
[4] Xiaoping Zhou,et al. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study , 2022, Journal for ImmunoTherapy of Cancer.
[5] Yujin Lee,et al. Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem , 2021, Scientific Reports.
[6] L. Lou,et al. Third‐generation EGFR inhibitor HS‐10296 in combination with famitinib, a multi‐targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR‐mutant non‐small cell lung cancer cells , 2021, Thoracic cancer.
[7] Christine M. Madla,et al. The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group. , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[8] M. Miccoli,et al. Sunitinib in the Treatment of Thyroid Cancer. , 2019, Current medicinal chemistry.
[9] Qingmei He,et al. Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study , 2018, Cancer communications.
[10] Xia Tao,et al. LC-MS/MS method for simultaneous determination of famitinib and its major metabolites in human plasma. , 2018, Bioanalysis.
[11] C. Lovly,et al. Mechanisms of receptor tyrosine kinase activation in cancer , 2018, Molecular Cancer.
[12] Z. Zuo,et al. A Review of Food–Drug Interactions on Oral Drug Absorption , 2017, Drugs.
[13] M. Ratain,et al. Food Effect Studies for Oncology Drug Products , 2017, Clinical pharmacology and therapeutics.
[14] Shuangbing Xu,et al. Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation , 2015, International journal of radiation biology.
[15] Jian Zhang,et al. Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer , 2014, Cancer Chemotherapy and Pharmacology.
[16] Xiaoyan Chen,et al. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib , 2013, Cancer Chemotherapy and Pharmacology.
[17] Xiaoyan Chen,et al. Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients , 2013, British journal of pharmacology.
[18] D. Greenblatt,et al. Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs , 2008, Journal of clinical pharmacology.
[19] D. Greenblatt,et al. The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates , 2005, Clinical Pharmacokinetics.
[20] H. Zhou,et al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. , 2000, British journal of clinical pharmacology.